It was reported that VEGF-A as a biomarker for the diagnosis of SCN had 100% sensitivity, 97% specificity, and a critical value of 8500 pg/mL, which helped to differentiate between SCN and precancerous/malignant pancreatic cysts, and afforded an opportunity for early detection, prevention, and cure [27]. The gene discussed is VEGFA; the disease is severe congenital neutropenia.